The estimated Net Worth of Stefani Wolff is at least $875 mil dollars as of 30 April 2023. Ms Wolff owns over 962 units of Nurix Therapeutics stock worth over $153,435 and over the last 5 years she sold NRIX stock worth over $334,368. In addition, she makes $387,252 as COO & Exec. VP of Product Devel. at Nurix Therapeutics.
Ms has made over 8 trades of the Nurix Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 962 units of NRIX stock worth $22,867 on 30 April 2023.
The largest trade she's ever made was exercising 5,505 units of Nurix Therapeutics stock on 16 December 2019 worth over $24,993. On average, Ms trades about 1,640 units every 95 days since 2019. As of 30 April 2023 she still owns at least 6,455 units of Nurix Therapeutics stock.
You can see the complete history of Ms Wolff stock trades at the bottom of the page.
Stefani A. Wolff is the COO & Exec. VP of Product Devel. at Nurix Therapeutics.
As the COO & Exec. VP of Product Devel. of Nurix Therapeutics, the total compensation of Ms Wolff at Nurix Therapeutics is $387,252. There are 4 executives at Nurix Therapeutics getting paid more, with Dr. Arthur T. Sands having the highest compensation of $852,767.
Ms Wolff is 59, she's been the COO & Exec. VP of Product Devel. of Nurix Therapeutics since . There are 1 older and 3 younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics, Inc. is Howard A. Simon J.D., Esq., SPHR, 62, who is the VP of Operations & Corp. Counsel.
Stefani's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Over the last 4 years, insiders at Nurix Therapeutics have traded over $1,236,800 worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall y Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $116,806. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth $42,173.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics executives and other stock owners filed with the SEC include: